<?xml version='1.0' encoding='utf-8'?>
<document id="30442649"><sentence text="Mechanisms and Clinical Significance of Pharmacokinetic-Based Drug-Drug Interactions with Drugs Approved by the U.S. Food and Drug Administration in 2017." /><sentence text="Pharmacokinetic-based drug-drug interaction (DDI) data for drugs approved by the U" /><sentence text="S" /><sentence text=" Food and Drug Administration in 2017 (N = 34) were analyzed using the University of Washington Drug Interaction Database" /><sentence text=" The mechanisms and clinical relevance of these interactions were characterized based on information from new drug application reviews" /><sentence text=" CYP3A inhibition and induction explained most of the observed drug interactions (new drugs as victims or as perpetrators), and transporters mediated about half of all DDIs, alone or with enzymes" /><sentence text=" Organic anion transporting polypeptide (OATP)1B1/1B3 played a significant role, mediating more than half of the drug interactions with area under the time-plasma curve (AUC) changes ≥5-fold" /><sentence text=" As victims, five new drugs were identified as sensitive substrates: abemeciclib, midostaurin, and neratinib for CYP3A and glecaprevir and voxilaprevir for OATP1B1/1B3"><entity charOffset="69-80" id="DDI-PubMed.30442649.s8.e0" text="abemeciclib" /><entity charOffset="82-93" id="DDI-PubMed.30442649.s8.e1" text="midostaurin" /><entity charOffset="99-108" id="DDI-PubMed.30442649.s8.e2" text="neratinib" /><entity charOffset="113-118" id="DDI-PubMed.30442649.s8.e3" text="CYP3A" /><entity charOffset="123-134" id="DDI-PubMed.30442649.s8.e4" text="glecaprevir" /><entity charOffset="139-151" id="DDI-PubMed.30442649.s8.e5" text="voxilaprevir" /><pair ddi="false" e1="DDI-PubMed.30442649.s8.e0" e2="DDI-PubMed.30442649.s8.e0" /><pair ddi="false" e1="DDI-PubMed.30442649.s8.e0" e2="DDI-PubMed.30442649.s8.e1" /><pair ddi="false" e1="DDI-PubMed.30442649.s8.e0" e2="DDI-PubMed.30442649.s8.e2" /><pair ddi="false" e1="DDI-PubMed.30442649.s8.e0" e2="DDI-PubMed.30442649.s8.e3" /><pair ddi="false" e1="DDI-PubMed.30442649.s8.e0" e2="DDI-PubMed.30442649.s8.e4" /><pair ddi="false" e1="DDI-PubMed.30442649.s8.e0" e2="DDI-PubMed.30442649.s8.e5" /><pair ddi="false" e1="DDI-PubMed.30442649.s8.e1" e2="DDI-PubMed.30442649.s8.e1" /><pair ddi="false" e1="DDI-PubMed.30442649.s8.e1" e2="DDI-PubMed.30442649.s8.e2" /><pair ddi="false" e1="DDI-PubMed.30442649.s8.e1" e2="DDI-PubMed.30442649.s8.e3" /><pair ddi="false" e1="DDI-PubMed.30442649.s8.e1" e2="DDI-PubMed.30442649.s8.e4" /><pair ddi="false" e1="DDI-PubMed.30442649.s8.e1" e2="DDI-PubMed.30442649.s8.e5" /><pair ddi="false" e1="DDI-PubMed.30442649.s8.e2" e2="DDI-PubMed.30442649.s8.e2" /><pair ddi="false" e1="DDI-PubMed.30442649.s8.e2" e2="DDI-PubMed.30442649.s8.e3" /><pair ddi="false" e1="DDI-PubMed.30442649.s8.e2" e2="DDI-PubMed.30442649.s8.e4" /><pair ddi="false" e1="DDI-PubMed.30442649.s8.e2" e2="DDI-PubMed.30442649.s8.e5" /><pair ddi="false" e1="DDI-PubMed.30442649.s8.e3" e2="DDI-PubMed.30442649.s8.e3" /><pair ddi="false" e1="DDI-PubMed.30442649.s8.e3" e2="DDI-PubMed.30442649.s8.e4" /><pair ddi="false" e1="DDI-PubMed.30442649.s8.e3" e2="DDI-PubMed.30442649.s8.e5" /><pair ddi="false" e1="DDI-PubMed.30442649.s8.e4" e2="DDI-PubMed.30442649.s8.e4" /><pair ddi="false" e1="DDI-PubMed.30442649.s8.e4" e2="DDI-PubMed.30442649.s8.e5" /></sentence><sentence text=" As perpetrators, three drugs were considered strong inhibitors: ribociclib for CYP3A, glecaprevir/pibrentasvir for OATP1B1/1B3, and sofosbuvir/velpatasvir/voxilaprevir for OATP1B1/1B3 and breast cancer resistance protein"><entity charOffset="87-98" id="DDI-PubMed.30442649.s9.e0" text="glecaprevir" /><entity charOffset="99-111" id="DDI-PubMed.30442649.s9.e1" text="pibrentasvir" /><entity charOffset="133-143" id="DDI-PubMed.30442649.s9.e2" text="sofosbuvir" /><entity charOffset="144-155" id="DDI-PubMed.30442649.s9.e3" text="velpatasvir" /><entity charOffset="156-168" id="DDI-PubMed.30442649.s9.e4" text="voxilaprevir" /><entity charOffset="80-91" id="DDI-PubMed.30442649.s9.e5" text="CYP3A" /><pair ddi="false" e1="DDI-PubMed.30442649.s9.e5" e2="DDI-PubMed.30442649.s9.e5" /><pair ddi="false" e1="DDI-PubMed.30442649.s9.e5" e2="DDI-PubMed.30442649.s9.e0" /><pair ddi="false" e1="DDI-PubMed.30442649.s9.e5" e2="DDI-PubMed.30442649.s9.e1" /><pair ddi="false" e1="DDI-PubMed.30442649.s9.e5" e2="DDI-PubMed.30442649.s9.e2" /><pair ddi="false" e1="DDI-PubMed.30442649.s9.e5" e2="DDI-PubMed.30442649.s9.e3" /><pair ddi="false" e1="DDI-PubMed.30442649.s9.e5" e2="DDI-PubMed.30442649.s9.e4" /><pair ddi="false" e1="DDI-PubMed.30442649.s9.e0" e2="DDI-PubMed.30442649.s9.e0" /><pair ddi="false" e1="DDI-PubMed.30442649.s9.e0" e2="DDI-PubMed.30442649.s9.e1" /><pair ddi="false" e1="DDI-PubMed.30442649.s9.e0" e2="DDI-PubMed.30442649.s9.e2" /><pair ddi="false" e1="DDI-PubMed.30442649.s9.e0" e2="DDI-PubMed.30442649.s9.e3" /><pair ddi="false" e1="DDI-PubMed.30442649.s9.e0" e2="DDI-PubMed.30442649.s9.e4" /><pair ddi="false" e1="DDI-PubMed.30442649.s9.e1" e2="DDI-PubMed.30442649.s9.e1" /><pair ddi="false" e1="DDI-PubMed.30442649.s9.e1" e2="DDI-PubMed.30442649.s9.e2" /><pair ddi="false" e1="DDI-PubMed.30442649.s9.e1" e2="DDI-PubMed.30442649.s9.e3" /><pair ddi="false" e1="DDI-PubMed.30442649.s9.e1" e2="DDI-PubMed.30442649.s9.e4" /><pair ddi="false" e1="DDI-PubMed.30442649.s9.e2" e2="DDI-PubMed.30442649.s9.e2" /><pair ddi="false" e1="DDI-PubMed.30442649.s9.e2" e2="DDI-PubMed.30442649.s9.e3" /><pair ddi="false" e1="DDI-PubMed.30442649.s9.e2" e2="DDI-PubMed.30442649.s9.e4" /><pair ddi="false" e1="DDI-PubMed.30442649.s9.e3" e2="DDI-PubMed.30442649.s9.e3" /><pair ddi="false" e1="DDI-PubMed.30442649.s9.e3" e2="DDI-PubMed.30442649.s9.e4" /></sentence><sentence text=" No strong inducer of enzymes or transporters was identified" /><sentence text=" DDIs with AUC changes ≥5-fold and almost all DDIs with AUC changes 2- to 5-fold had dose recommendations in their respective drug labels" /><sentence text=" A small fraction of DDIs with exposure changes &lt;2-fold had a labeling impact, mostly related to drugs with narrow therapeutic indices" /><sentence text=" As with drugs approved in recent years, all drugs found to be sensitive substrates or strong inhibitors of enzymes or transporters were among oncology or antiviral treatments, suggesting a serious risk of DDIs in these patient populations for whom effective therapy is already complex because of polytherapy" /><sentence text="" /></document>